Literature DB >> 9179367

Immunomodulatory effects of Viscum album agglutinin-I on natural immunity.

T Hajto1, K Hostanska, J Fischer, R Saller.   

Abstract

In 24 h cultured human peripheral blood mononuclear cells, treated with various (1 microgram/ml to 1 ng/ml) concentrations of Viscum album agglutinin-I, quantitative assessment of DNA breaks labelled with terminal deoxynucleotidyl transferase revealed a dose-dependent Viscum album agglutinin-I-induced apoptosis above a lectin concentration of 10 ng/ml. After 24 h incubation of peripheral blood mononuclear cells with non-cytotoxic concentrations of Viscum album agglutinin-I (10 and 1 ng/ml), messenger (m)RNA expression and secretion of a panel of cytokines were evaluated by reverse polymerase chain reaction and by enzyme-linked immunosorbent assay (ELISA), respectively. The lectin induced expression of interleukin-1 alpha, interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, interferon-gamma, granulocyte-monocyte colony stimulating factor and interleukin-10 genes, but no expression of interleukin-2 or interferon-gamma production could be detected. In addition, cellular components of the natural immune system (such as monocytes and granulocytes) bound Viscum album agglutinin-I molecules to a higher degree than lymphocytes. To establish the modulatory potency of Viscum album agglutinin-I on the natural immunity of human subjects, four randomized, double-blind crossover trials were performed on healthy volunteers. In contrast to the significant lectin-induced increases in number and activity of natural killer cells observed in animal models, in the first and second trial human healthy individuals showed no significant differences between their natural killer responses following an injection of lectin-enriched preparation or saline. Due to considerable intrinsic fluctuation of these parameters, a third and fourth double-blind trial with freshly isolated Viscum album agglutinin-I was performed using a more rapidly detectable parameter, the priming of granulocytes. Here, significant lectin-induced increases were found.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179367     DOI: 10.1097/00001813-199704001-00010

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro.

Authors:  U Elsässer-Beile; M Voss; R Schühle; U Wetterauer
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Anti-inflammatory effect of Viscum album agglutinin-I (VAA-I): induction of apoptosis in activated neutrophils and inhibition of lipopolysaccharide-induced neutrophilic inflammation in vivo.

Authors:  V Lavastre; H Cavalli; C Ratthe; D Girard
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 3.  Phytotherapy and Nutritional Supplements on Breast Cancer.

Authors:  C M Lopes; A Dourado; R Oliveira
Journal:  Biomed Res Int       Date:  2017-08-06       Impact factor: 3.411

4.  [Paraoxonase 1 gene polymorphism 192Q/R in old men and long-livers from Tatars ethnic group].

Authors:  V V Pauk; I A Tuktarova; T R Nasibullin; L P Zueva; A Kh Adel'guzhina; E K Khusnutdinova; O E Mustafina
Journal:  Mol Biol (Mosk)       Date:  2007 Jul-Aug

Review 5.  Preclinical and clinical effects of mistletoe against breast cancer.

Authors:  Mohsen Marvibaigi; Eko Supriyanto; Neda Amini; Fadzilah Adibah Abdul Majid; Saravana Kumar Jaganathan
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

6.  Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression.

Authors:  Peiying Yang; Yan Jiang; Yong Pan; Xiaoping Ding; Patrea Rhea; Jibin Ding; David H Hawke; Dean Felsher; Goutham Narla; Zhimin Lu; Richard T Lee
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

7.  Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model.

Authors:  A Thies; P Dautel; A Meyer; U Pfüller; U Schumacher
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.